Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Eli Lilly and Company (LLY) Insider Trading Activity
Healthcare • Drug Manufacturers - General • 43,000 employees
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Total Value
-$2,298,834,751.53
Total Shares
-709,889
Average Trade Value
-$13,288,062.15
Most Active Insider
Lilly Endowment Inc
Total Activity: $2,383,533,766
Largest Single Transaction
$1,599,999,998
by Lilly Endowment Inc on Feb 24, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
Mar 3, 2025 | 17,393 | $16,207,093 | 96,032,486 (-0.0%) | Sale | ||
Mar 3, 2025 | 25,057 | $23,321,552 | 96,049,879 (-0.0%) | Sale | ||
Mar 3, 2025 | 68,251 | $63,454,661 | 96,074,936 (-0.1%) | Sale | ||
Mar 3, 2025 | 25,984 | $24,138,720 | 96,143,187 (-0.0%) | Sale | ||
Mar 3, 2025 | 3,997 | $3,732,139 | 96,017,790 (-0.0%) | Sale | ||
Mar 3, 2025 | 812 | $759,130 | 96,016,978 (-0.0%) | Sale | ||
Mar 3, 2025 | 10,699 | $9,979,706 | 96,021,787 (-0.0%) | Sale | ||
Mar 3, 2025 | 3,691 | $3,416,220 | 96,198,597 (-0.0%) | Sale | ||
Mar 3, 2025 | 7,665 | $7,086,515 | 96,202,288 (-0.0%) | Sale | ||
Mar 3, 2025 | 8,197 | $7,567,905 | 96,209,953 (-0.0%) | Sale | ||
Mar 3, 2025 | 21,025 | $19,507,205 | 96,169,171 (-0.0%) | Sale | ||
Mar 3, 2025 | 18,828 | $17,367,343 | 96,218,150 (-0.0%) | Sale | ||
Mar 3, 2025 | 8,401 | $7,787,962 | 96,190,196 (-0.0%) | Sale | ||
EVP Pres., Mfg. Operations
Officer
|
Mar 1, 2025 | 1,260 | $1,159,994 | 39,748 (-3.2%) | Payment of Exercise Price | |
EVP Pres., Mfg. Operations
Officer
|
Mar 1, 2025 | 2,837 | $10,000 | 41,008 (+6.9%) | Exercise/Conversion | |
Evp, Chief People Officer
Officer
|
Mar 1, 2025 | 2,403 | $10,000 | 10,905 (+22.0%) | Exercise/Conversion | |
Evp, Chief People Officer
Officer
|
Mar 1, 2025 | 1,066 | $981,392 | 9,838 (-10.8%) | Payment of Exercise Price | |
Feb 25, 2025 | 50,118 | $45,184,685 | 96,376,282 (-0.1%) | Sale | ||
Feb 25, 2025 | 36,219 | $32,723,287 | 96,292,158 (-0.0%) | Sale | ||
Feb 25, 2025 | 3,290 | $2,991,870 | 96,240,854 (-0.0%) | Sale | ||
Feb 25, 2025 | 5,191 | $4,714,944 | 96,244,144 (-0.0%) | Sale | ||
Feb 25, 2025 | 3,606 | $3,283,382 | 96,237,248 (-0.0%) | Sale | ||
Feb 25, 2025 | 4,962 | $4,501,953 | 96,249,335 (-0.0%) | Sale | ||
Feb 25, 2025 | 8,559 | $7,758,391 | 96,254,297 (-0.0%) | Sale | ||
Feb 25, 2025 | 270 | $246,118 | 96,236,978 (-0.0%) | Sale | ||
Feb 25, 2025 | 18,159 | $16,425,542 | 96,273,999 (-0.0%) | Sale | ||
Feb 25, 2025 | 11,143 | $10,089,006 | 96,262,856 (-0.0%) | Sale | ||
Feb 25, 2025 | 47,905 | $43,233,592 | 96,328,377 (-0.0%) | Sale | ||
Feb 25, 2025 | 35,578 | $32,038,025 | 96,426,400 (-0.0%) | Sale | ||
Feb 24, 2025 | 6,444 | $5,653,392 | 96,515,966 (-0.0%) | Sale | ||
Feb 24, 2025 | 1,631 | $1,434,419 | 96,512,517 (-0.0%) | Sale | ||
Feb 24, 2025 | 1,818 | $1,599,999,998 | 96,514,148 (-0.0%) | Sale | ||
Feb 24, 2025 | 578 | $515,503 | 96,461,978 (-0.0%) | Sale | ||
Feb 24, 2025 | 2,569 | $2,288,578 | 96,462,556 (-0.0%) | Sale | ||
Feb 24, 2025 | 3,835 | $3,413,131 | 96,465,125 (-0.0%) | Sale | ||
Feb 24, 2025 | 4,230 | $3,760,373 | 96,468,960 (-0.0%) | Sale | ||
Feb 24, 2025 | 5,169 | $4,589,421 | 96,473,190 (-0.0%) | Sale | ||
Feb 24, 2025 | 5,754 | $5,102,987 | 96,478,359 (-0.0%) | Sale | ||
Feb 24, 2025 | 2,628 | $2,328,269 | 96,484,113 (-0.0%) | Sale | ||
Feb 24, 2025 | 1,700 | $1,503,891 | 96,486,741 (-0.0%) | Sale | ||
Feb 24, 2025 | 1,788 | $1,580,193 | 96,488,441 (-0.0%) | Sale | ||
Feb 24, 2025 | 6,361 | $5,614,168 | 96,490,229 (-0.0%) | Sale | ||
Feb 24, 2025 | 14,595 | $12,865,741 | 96,496,590 (-0.0%) | Sale | ||
Feb 24, 2025 | 1,332 | $1,172,957 | 96,511,185 (-0.0%) | Sale | ||
Feb 21, 2025 | 1,221 | $1,081,160 | 96,549,253 (-0.0%) | Sale | ||
Feb 21, 2025 | 19,490 | $17,145,548 | 96,572,064 (-0.0%) | Sale | ||
Feb 21, 2025 | 9,766 | $8,578,728 | 96,591,554 (-0.0%) | Sale | ||
Feb 21, 2025 | 6,152 | $5,486,304 | 96,527,333 (-0.0%) | Sale | ||
Feb 21, 2025 | 2,700 | $2,396,120 | 96,544,724 (-0.0%) | Sale | ||
Feb 21, 2025 | 5,182 | $4,583,194 | 96,550,474 (-0.0%) | Sale | ||
Feb 21, 2025 | 4,079 | $3,599,718 | 96,559,296 (-0.0%) | Sale | ||
Feb 21, 2025 | 20,542 | $18,021,764 | 96,601,320 (-0.0%) | Sale | ||
Feb 21, 2025 | 5,781 | $5,089,292 | 96,566,283 (-0.0%) | Sale | ||
Feb 21, 2025 | 3,640 | $3,215,671 | 96,555,656 (-0.0%) | Sale | ||
Feb 21, 2025 | 2,700 | $2,402,973 | 96,540,937 (-0.0%) | Sale | ||
Feb 21, 2025 | 1,087 | $966,066 | 96,543,637 (-0.0%) | Sale | ||
Feb 21, 2025 | 7,452 | $6,638,406 | 96,533,485 (-0.0%) | Sale | ||
Feb 21, 2025 | 3,357 | $2,997,059 | 96,523,976 (-0.0%) | Sale | ||
Feb 21, 2025 | 1,829 | $1,621,297 | 96,547,424 (-0.0%) | Sale | ||
Feb 21, 2025 | 2,908 | $2,563,594 | 96,563,375 (-0.0%) | Sale | ||
Feb 21, 2025 | 1,566 | $1,399,613 | 96,522,410 (-0.0%) | Sale | ||
Feb 20, 2025 | 8,937 | $7,841,646 | 96,627,610 (-0.0%) | Sale | ||
Feb 20, 2025 | 200 | $176,029 | 96,621,862 (-0.0%) | Sale | ||
Feb 20, 2025 | 3,127 | $2,746,450 | 96,624,483 (-0.0%) | Sale | ||
Feb 20, 2025 | 2,421 | $2,129,228 | 96,622,062 (-0.0%) | Sale | ||
Feb 19, 2025 | 1,293 | $1,138,413 | 96,636,547 (-0.0%) | Sale | ||
Feb 19, 2025 | 1,467 | $1,288,771 | 96,640,229 (-0.0%) | Sale | ||
Feb 19, 2025 | 2,389 | $2,101,126 | 96,637,840 (-0.0%) | Sale | ||
Feb 19, 2025 | 4,836 | $4,242,976 | 96,641,696 (-0.0%) | Sale | ||
Director
|
Feb 18, 2025 | 11 | $9,429 | 72,683 (+0.0%) | Grant | |
Director
|
Feb 18, 2025 | 17 | $14,572 | 16,228 (+0.1%) | Grant | |
Director
|
Feb 18, 2025 | 13 | $11,144 | 54,719 (+0.0%) | Grant | |
Director
|
Feb 18, 2025 | 11 | $9,429 | 1,903 (+0.6%) | Grant | |
Director
|
Feb 18, 2025 | 5 | $4,286 | 2,545 (+0.2%) | Grant | |
Feb 13, 2025 | 6,470 | $5,683,106 | 96,664,979 (-0.0%) | Sale | ||
Feb 13, 2025 | 10,529 | $9,238,892 | 96,671,449 (-0.0%) | Sale | ||
Feb 13, 2025 | 3,175 | $2,796,511 | 96,656,646 (-0.0%) | Sale | ||
Feb 13, 2025 | 5,158 | $4,536,796 | 96,659,821 (-0.0%) | Sale | ||
Feb 13, 2025 | 6,789 | $5,985,379 | 96,649,857 (-0.0%) | Sale | ||
Feb 13, 2025 | 3,025 | $2,669,677 | 96,646,832 (-0.0%) | Sale | ||
Feb 13, 2025 | 300 | $265,034 | 96,646,532 (-0.0%) | Sale | ||
Evp, Cso Pres. Lrl Lly Imm
Officer
|
Feb 10, 2025 | 18,771 | $16,309,746 | 136,660 (+13.7%) | Grant | |
EVP Pres., Mfg. Operations
Officer
|
Feb 10, 2025 | 5,974 | $5,190,689 | 38,171 (+15.7%) | Grant | |
Evp, Gc Secretary
Officer
|
Feb 10, 2025 | 10,320 | $8,966,842 | 28,837 (+35.8%) | Grant | |
President, Chair, and CEO
Director, Officer
|
Feb 10, 2025 | 55,131 | $47,902,223 | 539,613 (+10.2%) | Grant | |
Evp, Cso Pres. Lrl Lly Imm
Officer
|
Feb 10, 2025 | 340 | $293,750 | 118,598 (-0.3%) | Sale | |
Evp, Cso Pres. Lrl Lly Imm
Officer
|
Feb 10, 2025 | 710 | $614,690 | 117,888 (-0.6%) | Sale | |
Evp, Cso Pres. Lrl Lly Imm
Officer
|
Feb 10, 2025 | 3,950 | $3,407,626 | 118,938 (-3.3%) | Sale | |
EVP Pres, Lilly Neuroscience
Officer
|
Feb 10, 2025 | 6,828 | $5,932,713 | 74,209 (+9.2%) | Grant | |
EVP Pres., Lilly Oncology
Officer
|
Feb 10, 2025 | 6,103 | $5,302,775 | 19,561 (+31.2%) | Grant | |
EVP CFO
Officer
|
Feb 10, 2025 | 2,895 | $2,515,408 | 13,969 (+20.7%) | Grant | |
Svp, Finance, Cao
Officer
|
Feb 10, 2025 | 1,359 | $1,180,808 | 6,839 (+19.9%) | Grant | |
EVP President, Lly Int'l
Officer
|
Feb 10, 2025 | 7,123 | $6,189,032 | 28,759 (+24.8%) | Grant | |
Evp, Hr Diversity
Officer
|
Feb 10, 2025 | 919 | $798,501 | 8,962 (+10.3%) | Grant | |
Evppres, Cardmethlth, Lly Usa
Officer
|
Feb 10, 2025 | 7,170 | $6,229,870 | 53,650 (+13.4%) | Grant | |
EVP Cido
Officer
|
Feb 10, 2025 | 6,815 | $5,921,417 | 19,718 (+34.6%) | Grant | |
Feb 6, 2025 | 18,918 | $16,483,689 | 96,803,393 (-0.0%) | Sale | ||
Feb 6, 2025 | 15,637 | $13,657,715 | 96,775,600 (-0.0%) | Sale | ||
Feb 6, 2025 | 12,726 | $11,204,670 | 96,701,727 (-0.0%) | Sale | ||
Feb 6, 2025 | 12,156 | $10,602,937 | 96,791,237 (-0.0%) | Sale | ||
Feb 6, 2025 | 28,727 | $25,003,579 | 96,822,311 (-0.0%) | Sale | ||
Feb 6, 2025 | 2,239 | $1,975,781 | 96,695,337 (-0.0%) | Sale | ||
Feb 6, 2025 | 4,855 | $4,289,592 | 96,690,482 (-0.0%) | Sale | ||
Feb 6, 2025 | 5,736 | $4,979,984 | 96,874,409 (-0.0%) | Sale | ||
Feb 6, 2025 | 15,032 | $13,143,199 | 96,760,568 (-0.0%) | Sale | ||
Feb 6, 2025 | 9,301 | $8,140,291 | 96,751,267 (-0.0%) | Sale | ||
Feb 6, 2025 | 9,278 | $8,141,213 | 96,733,089 (-0.0%) | Sale | ||
Feb 6, 2025 | 6,228 | $5,470,439 | 96,726,861 (-0.0%) | Sale | ||
Feb 6, 2025 | 12,408 | $10,913,382 | 96,714,453 (-0.0%) | Sale | ||
Feb 6, 2025 | 2,700 | $2,391,422 | 96,684,577 (-0.0%) | Sale | ||
Feb 6, 2025 | 2,325 | $2,061,491 | 96,682,252 (-0.0%) | Sale | ||
Feb 6, 2025 | 274 | $243,125 | 96,681,978 (-0.0%) | Sale | ||
Feb 6, 2025 | 5,070 | $4,390,960 | 96,886,908 (-0.0%) | Sale | ||
Feb 6, 2025 | 6,763 | $5,864,779 | 96,880,145 (-0.0%) | Sale | ||
Feb 6, 2025 | 3,205 | $2,835,024 | 96,687,277 (-0.0%) | Sale | ||
Feb 6, 2025 | 4,151 | $3,658,563 | 96,697,576 (-0.0%) | Sale | ||
Feb 6, 2025 | 8,900 | $7,800,770 | 96,742,367 (-0.0%) | Sale | ||
Feb 6, 2025 | 23,371 | $20,314,657 | 96,851,038 (-0.0%) | Sale | ||
EVP President, Lly Int'l
Officer
|
Feb 1, 2025 | 3,269 | $10,000 | 23,071 (+14.2%) | Exercise/Conversion | |
Evp, Cso Pres. Lrl Lly Imm
Officer
|
Feb 1, 2025 | 8,989 | $10,000 | 126,892 (+7.1%) | Exercise/Conversion | |
Evp, Cso Pres. Lrl Lly Imm
Officer
|
Feb 1, 2025 | 4,003 | $3,246,753 | 122,888 (-3.3%) | Payment of Exercise Price | |
EVP Pres., Lilly Oncology
Officer
|
Feb 1, 2025 | 1,409 | $1,142,812 | 13,458 (-10.5%) | Payment of Exercise Price | |
EVP President, Lly Int'l
Officer
|
Feb 1, 2025 | 1,434 | $1,163,089 | 21,636 (-6.6%) | Payment of Exercise Price | |
Evppres, Cardmethlth, Lly Usa
Officer
|
Feb 1, 2025 | 3,433 | $10,000 | 48,016 (+7.1%) | Exercise/Conversion | |
President, Chair, and CEO
Director, Officer
|
Feb 1, 2025 | 11,903 | $9,654,285 | 484,481 (-2.5%) | Payment of Exercise Price | |
President, Chair, and CEO
Director, Officer
|
Feb 1, 2025 | 26,561 | $10,000 | 496,385 (+5.4%) | Exercise/Conversion | |
EVP Pres., Mfg. Operations
Officer
|
Feb 1, 2025 | 1,281 | $1,038,993 | 32,197 (-4.0%) | Payment of Exercise Price | |
Evppres, Cardmethlth, Lly Usa
Officer
|
Feb 1, 2025 | 1,535 | $1,245,008 | 46,480 (-3.3%) | Payment of Exercise Price | |
EVP Pres., Lilly Oncology
Officer
|
Feb 1, 2025 | 3,023 | $10,000 | 14,868 (+20.3%) | Exercise/Conversion | |
EVP Pres, Lilly Neuroscience
Officer
|
Feb 1, 2025 | 3,269 | $10,000 | 68,838 (+4.7%) | Exercise/Conversion | |
EVP Cido
Officer
|
Feb 1, 2025 | 1,466 | $1,189,043 | 12,903 (-11.4%) | Payment of Exercise Price | |
EVP Cido
Officer
|
Feb 1, 2025 | 3,269 | $10,000 | 14,370 (+22.7%) | Exercise/Conversion | |
EVP Pres, Lilly Neuroscience
Officer
|
Feb 1, 2025 | 1,457 | $1,181,744 | 67,380 (-2.2%) | Payment of Exercise Price | |
Evp, Gc Secretary
Officer
|
Feb 1, 2025 | 2,166 | $1,756,799 | 18,516 (-11.7%) | Payment of Exercise Price | |
Evp, Gc Secretary
Officer
|
Feb 1, 2025 | 4,904 | $10,000 | 20,683 (+23.7%) | Exercise/Conversion | |
EVP Pres., Mfg. Operations
Officer
|
Feb 1, 2025 | 2,861 | $10,000 | 33,479 (+8.5%) | Exercise/Conversion | |
Director
|
Jan 21, 2025 | 6 | $4,454 | 2,539 (+0.2%) | Grant | |
Director
|
Jan 21, 2025 | 13 | $9,651 | 72,671 (+0.0%) | Grant | |
Director
|
Jan 21, 2025 | 13 | $9,651 | 1,892 (+0.7%) | Grant | |
Director
|
Jan 21, 2025 | 19 | $14,105 | 16,211 (+0.1%) | Grant | |
Director
|
Jan 21, 2025 | 15 | $11,135 | 54,705 (+0.0%) | Grant | |
Director
|
Dec 16, 2024 | 12 | $9,348 | 2,532 (+0.5%) | Grant | |
Director
|
Dec 16, 2024 | 19 | $14,801 | 16,191 (+0.1%) | Grant | |
Director
|
Dec 16, 2024 | 12 | $9,348 | 3,032 (+0.4%) | Grant | |
Director
|
Dec 16, 2024 | 12 | $9,348 | 1,878 (+0.6%) | Grant | |
Director
|
Dec 16, 2024 | 15 | $11,685 | 54,689 (+0.0%) | Grant | |
Director
|
Nov 18, 2024 | 302 | $219,614 | 54,586 (+0.6%) | Grant | |
Director
|
Nov 18, 2024 | 320 | $232,704 | 72,540 (+0.4%) | Grant | |
Director
|
Nov 18, 2024 | 13 | $9,454 | 2,214 (+0.6%) | Grant | |
Director
|
Nov 18, 2024 | 302 | $219,614 | 16,146 (+1.9%) | Grant | |
Director
|
Nov 18, 2024 | 20 | $14,544 | 15,844 (+0.1%) | Grant | |
Director
|
Nov 18, 2024 | 302 | $219,614 | 6,248 (+4.8%) | Grant | |
Director
|
Nov 18, 2024 | 13 | $9,454 | 1,561 (+0.8%) | Grant | |
Director
|
Nov 18, 2024 | 302 | $219,614 | 3,015 (+10.0%) | Grant | |
Director
|
Nov 18, 2024 | 302 | $219,614 | 23,118 (+1.3%) | Grant | |
Director
|
Nov 18, 2024 | 13 | $9,454 | 2,712 (+0.5%) | Grant | |
Director
|
Nov 18, 2024 | 302 | $219,614 | 1,864 (+16.2%) | Grant | |
Director
|
Nov 18, 2024 | 302 | $219,614 | 9,153 (+3.3%) | Grant | |
Director
|
Nov 18, 2024 | 16 | $11,635 | 54,283 (+0.0%) | Grant | |
Director
|
Nov 18, 2024 | 302 | $219,614 | 21,464 (+1.4%) | Grant | |
Director
|
Nov 18, 2024 | 302 | $219,614 | 2,516 (+12.0%) | Grant | |
Svp, Finance, Cao
Officer
|
Nov 8, 2024 | 900 | $723,042 | 5,480 (-16.4%) | Sale | |
Evp, Hr Diversity
Officer
|
Nov 1, 2024 | 1,534 | $10,000 | 8,724 (+17.6%) | Exercise/Conversion | |
EVP CFO
Officer
|
Nov 1, 2024 | 1,074 | $10,000 | 11,541 (+9.3%) | Exercise/Conversion | |
EVP Pres., Mfg. Operations
Officer
|
Nov 1, 2024 | 750 | $614,198 | 30,618 (-2.4%) | Payment of Exercise Price | |
Evp, Hr Diversity
Officer
|
Nov 1, 2024 | 681 | $557,691 | 8,042 (-8.5%) | Payment of Exercise Price | |
EVP Pres., Mfg. Operations
Officer
|
Nov 1, 2024 | 1,687 | $10,000 | 31,369 (+5.4%) | Exercise/Conversion | |
EVP CFO
Officer
|
Nov 1, 2024 | 467 | $382,440 | 11,073 (-4.2%) | Payment of Exercise Price | |
Director
|
Oct 21, 2024 | 13 | $11,780 | 54,267 (+0.0%) | Grant | |
Director
|
Oct 21, 2024 | 11 | $9,967 | 1,548 (+0.7%) | Grant | |
Director
|
Oct 21, 2024 | 16 | $14,498 | 15,825 (+0.1%) | Grant | |
Director
|
Oct 21, 2024 | 11 | $9,967 | 2,201 (+0.5%) | Grant | |
Director
|
Oct 21, 2024 | 11 | $9,967 | 2,699 (+0.4%) | Grant |